These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 30397066)
41. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ; Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051 [TBL] [Abstract][Full Text] [Related]
42. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776 [TBL] [Abstract][Full Text] [Related]
43. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children. Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459 [TBL] [Abstract][Full Text] [Related]
48. Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment. Higa N; Pelz A; Birch D; Beck IA; Sils T; Samson P; Bwakura-Dangarembizi M; Bolton-Moore C; Capparelli E; Chadwick E; Frenkel LM J Pediatric Infect Dis Soc; 2020 Apr; 9(2):261-264. PubMed ID: 31194860 [TBL] [Abstract][Full Text] [Related]
54. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241 [TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. Atwine D; Bonnet M; Taburet AM Br J Clin Pharmacol; 2018 Aug; 84(8):1641-1658. PubMed ID: 29624706 [TBL] [Abstract][Full Text] [Related]
58. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A; Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590 [TBL] [Abstract][Full Text] [Related]
59. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]